ImmunityBio (IBRX) Non-Current Deferred Tax Liability (2015 - 2022)

ImmunityBio (IBRX) has 7 years of Non-Current Deferred Tax Liability data on file, last reported at $162000.0 in Q2 2022.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 4.71% year-over-year to $162000.0 in Q2 2022; TTM through Jun 2022 was $162000.0, a 4.71% decrease from a year earlier, with the FY2021 full-year figure at $162000.0, down 96.65% from the prior year.
• Non-Current Deferred Tax Liability for Q2 2022 stood at $162000.0, roughly flat from $162000.0 in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for IBRX reached as high as $4.8 million in Q4 2020 and fell as low as $122000.0 in Q3 2018.
• Historically, Non-Current Deferred Tax Liability has averaged $658000.0 across 4 years, with a median of $170000.0 in 2021.
• Across the five-year window, Non-Current Deferred Tax Liability sank 96.65% in 2021 and declined 4.71% in 2022, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $122000.0 in 2018, then surged by 3865.57% to $4.8 million in 2020, then sank by 96.65% to $162000.0 in 2021, then changed by 0.0% to $162000.0 in 2022.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $162000.0 in Q2 2022, $162000.0 in Q1 2022, and $162000.0 in Q4 2021.